Release date: 4 April 2017
Promoter – Financial Intermediary
GRIFOLS SALocation
Description
Financing the promoter's R&D programme for new plasma proteins for various therapeutic areas, including Alzheimer's disease, liver cirrhosis, diabetes and cystic fibrosis.
Objectives
The project covers all stages of development i.e. pre-clinical development as well as clinical development of new health treatments. The project will be managed from the company's headquarters in Barcelona, Spain.
Sector(s)
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 170 million
Total cost (Approximate amount)
EUR 502 million
Environmental aspects
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Status
Signed - 5/12/2017
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).